Clinical Trials Logo

Clinical Trial Summary

A multicenter, randomized, double-blinded, placebo-controlled study of two dosing frequencies of recombinant Interleukin-7 (CYT107) treatment to restore absolute lymphocyte counts in sepsis patients; IRIS-7A (Immune Reconstitution of Immunosuppressed Sepsis patients).

A parallel study will be performed in United State of America to allow a common statistical analysis of the primary end points and analysis for the enrolled patient population.


Clinical Trial Description

Sepsis is the leading cause of death in critically ill patients in most intensive care units in Europe and the US. Recently, evidence has accumulated that sepsis progresses from a state of hyper-inflammation to a state of immunosuppression. This immunosuppressive phase is characterized by increased incidence of secondary infections often with relatively avirulent opportunistic type pathogens. Currently, new therapeutic approaches to sepsis are occurring using immuno-adjuvants that boost host immunity. One of the most promising agents Interleukin-7 is an essential, non-redundant, pluripotent cytokine produced mainly by bone marrow and thymic stromal cells that is required for T-cell survival.In addition to its anti-apoptotic properties, IL-7 induces potent proliferation of naïve and memory T-cells potentially supporting replenishment of the peripheral T-cell pool which is severely depleted during sepsis. These effects were confirmed in clinical trials at the National Cancer Institute and in HIV+ patients.

This clinical study will test the ability of IL-7 to restore the absolute lymphocyte counts in septic patients who have markedly reduced levels of circulating lymphocytes. An effect already confirmed in preclinical models of sepsis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02797431
Study type Interventional
Source University Hospital, Limoges
Contact
Status Terminated
Phase Phase 2
Start date January 14, 2016
Completion date November 13, 2017

See also
  Status Clinical Trial Phase
Not yet recruiting NCT02449928 - Using Sodium Lactate Ringer's Injection Resuscitate Septic Shock Patients N/A
Recruiting NCT02339649 - Long-term Cognitive and Cerebral Changes in Sepsis Survivors and Their Predictors N/A
Recruiting NCT05108467 - Saving Lives by Early Detection and Treatment of Sepsis and Septic Shock by Point of Care Lactate Test in Adults
Completed NCT03977688 - Evaluating a CytoSorb Score in Septic Shock
Completed NCT02353910 - VTE Incidence in Severe Sepsis and Septic Shock N/A
Completed NCT02640807 - A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Phase 2
Completed NCT02135770 - Impact of Low Dose Unfractionated Heparin Treatment on Inflammation in Sepsis Phase 3